Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01702428 · ClinicalTrials.gov registry record · Phase 3

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

A Phase 3 study of Measles and Mumps, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 3
Development phase
5,016
Enrollment target
20
Study locations

NCT01702428 is a Phase 3 study of Measles and Mumps that has completed, run by GlaxoSmithKline. The registered enrollment target is 5,016 participants, above the 1,482-participant average among 4 other Measles trials with a reported enrollment target (238% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01702428, a Phase 3 study of Measles and Mumps, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 3
Development phase
5,016 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate consistency in terms of the immune response to three different lots of GSK Biologicals' trivalent MMR vaccine manufactured to target potencies, and compare its immunogenicity to Merck \& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).

Conditions Studied

Measles Mumps Rubella

Interventions

  • BIOLOGICAL Priorix
  • BIOLOGICAL M-M-R II
  • BIOLOGICAL Varivax
  • BIOLOGICAL Havrix
  • BIOLOGICAL Prevnar 13

Study Locations (20)

California

  • GSK Investigational Site - Anaheim
  • GSK Investigational Site - Daly City
  • GSK Investigational Site - Fresno
  • GSK Investigational Site - Hayward
  • GSK Investigational Site - Los Gatos
  • GSK Investigational Site - Mission Hills
  • GSK Investigational Site - Paramount
  • GSK Investigational Site - Pleasanton
  • GSK Investigational Site - Sacramento
  • GSK Investigational Site - Sacramento
  • GSK Investigational Site - Santa Clara
  • GSK Investigational Site - Walnut Creek

Colorado

  • GSK Investigational Site - Colorado Springs
  • GSK Investigational Site - Colorado Springs

Alabama

  • GSK Investigational Site - Dothan

Arizona

  • GSK Investigational Site - Phoenix

Arkansas

  • GSK Investigational Site - Fayetteville

Idaho

  • GSK Investigational Site - Nampa

Illinois

  • GSK Investigational Site - Evergreen Park

Iowa

  • GSK Investigational Site - Ames

Trial Details

FieldValue
Enrollment Target 5,016 participants
Start Date 2012-11-09
Est. Completion 2015-04-16
Phase Phase 3

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01702428

The ClinicalTrials.gov registry entry for NCT01702428 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,016 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,482-participant average among 4 other Measles trials with a reported enrollment target (238% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Measles appearing as the primary indexed condition, and to 5 interventions - of which Priorix is the first listed.

NCT01702428 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Colorado, Alabama.

Frequently Asked Questions

What is clinical trial NCT01702428 about?

NCT01702428 is a clinical study titled "Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age". The purpose of this study is to evaluate consistency in terms of the immune response to three different lots of GSK Biologicals' trivalent MMR vaccine manufactured to target potencies, and compare its immunogenicity to Merck \& Co., Inc.'s MMR vaccine, which is approved for use in the United States ...

What is the current status of trial NCT01702428?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,016 participants. The study started on 2012-11-09. Estimated completion is 2015-04-16.

What conditions does trial NCT01702428 study?

This clinical trial studies the following conditions: Measles, Mumps, Rubella.

What interventions are being tested in trial NCT01702428?

The interventions under investigation include: Priorix (BIOLOGICAL), M-M-R II (BIOLOGICAL), Varivax (BIOLOGICAL), Havrix (BIOLOGICAL), Prevnar 13 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01702428?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01702428 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Measles

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Measles

All registered trials for this condition

Mumps

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.